Due to the unique nature of its anatomical location, the adenocarcinoma of esophagogastric junction (AEG) has been a subject of controversy and disagreement including its definition, staging, and treatment strategies. Chinse expert Consensus on Surgical Treatment of Adenocarcinoma of Esophagogastric Junction in China (2018 Edition) had been released in September 2018 and had played a pioneering role in unifying thoracic and general surgeons in China on surgical treatment strategies for AEG. Over the past five years, the emergence of several clinical research results on AEG has provided new clinical evidence for the selection of key surgical treatment strategies. Therefore, to further standardize the surgical treatment of AEG in China, Chinese Expert Consensus on Surgical Treatment of Adenocarcinoma of Esophagogastric Junction in China (2024 Edition) was released in 2024 by Chinese expert panel including 25 gastrointestinal surgeons and 24 thoracic surgeons. Based on the highest-level clinical research evidence in recent 5 years, this consensus ultimately formulates 29 recommendations on hotspots and key points on surgical treatment of AEG and summary 5 issues that are still awaiting further exploration. This review will provide a summary and detailed interpretation of the recommendations outlined in this consensus.
食管胃结合部腺癌（AEG）由于解剖位置的特殊性，其定义、分期及治疗策略存在诸多分歧与争议。2018年9月，我国发布了首部《食管胃结合部腺癌外科治疗中国专家共识（2018年版）》，积极推动了胸外科和普通外科医师AEG外科治疗策略的规范性和一致性。5年来，多项AEG临床研究结果的呈现，为AEG的外科治疗关键环节策略的选择提供了新的临床证据。因此，为进一步提升我国AEG外科临床实践的诊疗水平，在中国医师协会内镜医师分会腹腔镜外科专业组、国际食管疾病学会中国分会（CSDE）、中国食管胃结合部腺癌研究协作组、中国抗癌协会胃癌专委会和中华医学会肿瘤分会胃肠肿瘤学组的共同牵头和组织下，由25名胃肠外科专家和24名胸外科专家组成2024版食管胃结合部腺癌外科治疗中国专家共识编审专家组进行讨论修订，主要基于近5年来高级别临床研究证据完成共识的更新。最终形成了29项AEG外科治疗相关的推荐陈述，并提出了5项尚待探索的外科问题。本文主要针对修订后的共识推荐陈述进行解读。.